Moderna Inc (NAS:MRNA)
$ 141.01 8.11 (6.1%) Market Cap: 54.04 Bil Enterprise Value: 43.65 Bil PE Ratio: 0 PB Ratio: 4.21 GF Score: 68/100

Moderna Inc at Piper Sandler Healthcare Conference Transcript

Nov 30, 2023 / 05:30PM GMT
Release Date Price: $77.7 (-1.66%)
Edward Andrew Tenthoff;James M. Mock<
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Hello, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin our next presentation, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Moderna, which are located both at the back of the room and also at the registration desk.

As you all probably are well familiar by this point, Moderna is the leading developer of Messenger RNA or mRNA vaccines and medicines. mRNA shares have been under significant pressure over the last 2 years with the waning of the COVID pandemic. It just shows you, you do a good turn and then everybody forgets you. However, we really believe the company is in the strongest position in its history with a strong balance sheet, fundamentally derisk technology and a late-stage clinical pipeline with several upcoming approvals over the next several years.

Here from Moderna is CFO, Jamey Mock. Jamey, thanks for being with us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot